This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Macedo A, Monteiro I, Ray JA, Cirrincione A, Andrade S, Pereira C.Cost-effectiveness of treatment with trastuzumab in patients with early breast cancer from the Portuguese societal perspective. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 472 abstr. PCN40, 8 Nov 2008
Essers BA, Tjan Heijnen V, Severens JL, Novák A, oron U, Pompen M, Joore MA.Economic evaluation of trastuzumab for the adjuvant treatment of HER2 positive early breast cancer in The Netherlands. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 472 abstr. PCN41, 8 Nov 2008
Rubio-Terrés C, Gómez-Codina J, Ríos Herranz E, Castro AJ, Varela C, Ray JA.Pharmacoeconomic analysis of the addition of rituximab to first-line chemotherapy treatment regimens in Spanish patients with advanced follicular lymphoma. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 481 abstr. PCN69, 8 Nov 2008
Nagy B, Kutikova L, Stastny M, Vasile K, Zsolnai Nagy I, Mayer J.An economic evaluation of dasatinib (Sprycel (Rm)) in chronic phase chronic myeloid leukemia in central and eastern Europe. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 358 abstr. CN8, 8 Nov 2008
Negreiro F, Pereira C, Pereira H, Silva C.Economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as 2nd or 3rd line treatment of non-small cell lung cancer. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 476 abstr. PCN52, 8 Nov 2008
Rights and permissions
About this article
Cite this article
Cancer news from ISPOR. Pharmacoecon. Outcomes News 567, 6–7 (2008). https://doi.org/10.2165/00151234-200805670-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805670-00006